oral glp-1 agonist approved Danuglipron: An GLP-1R Competing with Peptide Injectables for Diabetes and Obesity Peptide GLP-1 receptor agonists: From

Description

This, however, does not apply to other GLP-1RAs approved for the treatment of T2DM, including the same liraglutide (Victoza) and semaglutide (Ozempic or Rybelsus) at lower dosages, prompting several stakeholders to request an updated guidance 232 and more caution in media enthusiasm 233

Manic episodes

Within participants with pre-existing SUDs, initiation of a GLP-1 receptor agonist was associated with reduced risk of SUD related emergency department visits (hazard ratio 0.69 (95% CI 0.61 to 0.78), NRD 8.92 (95% CI 11.59 to 6.25)), SUD related hospital admission (0.74 (0.65 to 0.85), NRD 6.23 (8.73 to 3.74)), and SUD related mortality (0.50 (0.32 to 0.79), NRD 1.52 (2.32 to 0.72)), and associated with reduced risk of the composite endpoint of the three outcomes (0.71 (0.65 to 0.79), NRD 11.79 (14.98 to 8.60)) (fig 6 and supplementary table S11)